Have a personal or library account? Click to login
Interpretation of Gamma Index for Quality Assurance of Simultaneously Integrated Boost (SIB) IMRT Plans for Head and Neck Carcinoma Cover

Interpretation of Gamma Index for Quality Assurance of Simultaneously Integrated Boost (SIB) IMRT Plans for Head and Neck Carcinoma

Open Access
|Dec 2017

References

  1. [1] Kouloulias V, Antypas C, Liakouli Z, et al. The first implementation of IMRT technique for head & neck and prostate cancer patients in public sector in Greece: feasibility, treatment planning and dose delivery verification using the delta (4PT) Pre-Treatment volumetric quality assurance system. J BUON. 2014;20(1):196-205.
  2. [2] Roxby KJ, Crosbie JC. Pre-treatment verification of intensity modulated radiation therapy plans using a commercial electronic portal dosimetry system. Australas Phys Eng Sci Med. 2010;33(1):51-57.10.1007/s13246-010-0001-0
  3. [3] Franceschini D, Paiar F, Meattini I, et al. Simultaneous integrated boost–intensity-modulated radiotherapy in head and neck cancer. Laryngoscope. 2013;123(12):E97-103.10.1002/lary.24257
  4. [4] Mohan R, Wu Q, Manning M, Schmidt-Ullrich R. Radiobiological considerations in the design of fractionation strategies for intensity-modulated radiation therapy of head and neck cancers. Int J Radiat Oncol Biol Phys. 2000;46(3):619-630.10.1016/S0360-3016(99)00438-1
  5. [5] Krishnan J, Rao S, Hegde S, Shetty J. A Dosimetric Comparison of Double Arc Volumetric Modulated Arc Therapy with Large Field Intensity Modulated Radiation Therapy for Head and Neck Cancer. IJMPCERO. 2015;4(4):353-363.10.4236/ijmpcero.2015.44042
  6. [6] Suzuki M, Nakamatsu K, Kanamori S, et al. Feasibility study of the simultaneous integrated boost (SIB) method for malignant gliomas using intensity-modulated radiotherapy (IMRT). Jpn J Clin Oncol. 2003;33(6):271-277.10.1093/jjco/hyg053
  7. [7] Elawady RA, Attalla EM, Elshemey WM, et al. Dose verification of intensity modulated radiotherapy in head and neck tumors. Int J Cancer Ther Oncol. 2014;2(3):02037.10.14319/ijcto.0203.7
  8. [8] Agazaryan N, Solberg TD, DeMarco JJ. Patient specific quality assurance for the delivery of intensity modulated radiotherapy. J Appl Clin Med Phys. 2003;4(1):40-50.10.1120/jacmp.v4i1.2540
  9. [9] Depuydt T, Van Esch A, Huyskens DP. A quantitative evaluation of IMRT dose distributions: refinement and clinical assessment of the gamma evaluation. Radiother Oncol. 2002;62(3):309-319.10.1016/S0167-8140(01)00497-2
  10. [10] Low DA, Dempsey JF. Evaluation of the gamma dose distribution comparison method. Med Phys. 2003;30(9):2455-2464.10.1118/1.159871114528967
  11. [11] Mijheer B, Georg D. Guidelines for the verification of IMRT. Brussels, Belgium: ESTRO; 2008.
  12. [12] Ezzell GA, Burmeister JW, Dogan N, et al. IMRT commissioning: multiple institution planning and dosimetry comparisons, a report from AAPM Task Group 119. Med Phys. 2009;36(11):5359-5373.10.1118/1.323810419994544
  13. [13] Tonigan JR. Evaluation of intensity modulated radiation therapy (IMRT) delivery error due to IMRT treatment plan complexity and improperly matched dosimetry data. MSc Thesis. The University of Texas. Houston, Texas; 2011.
  14. [14] Varatharaj C, Ravikumar M, Sathiyan S, et al. Dosimetric verification of brain and head and neck intensity-modulated radiation therapy treatment using EDR2 films and 2D ion chamber array matrix. J Cancer Res Ther. 2010;6(2):179-184.10.4103/0973-1482.6523320622365
  15. [15] Stasi M, Bresciani S, Miranti A, et al. Pretreatment patient-specific IMRT quality assurance: A correlation study between gamma index and patient clinical dose volume histogram. Med Phys. 2012;39(12):7626-7634.10.1118/1.476776323231310
  16. [16] Caivano R, Califano G, Fiorentino A, et al. Clinically relevant quality assurance for intensity modulated radiotherapy plans: gamma maps and DVH-based evaluation. Cancer Invest. 2014;32(3):85-91.10.3109/07357907.2013.87747824499109
  17. [17] Li H, Dong L, Zhang L, et al. Toward a better understanding of the gamma index: Investigation of parameters with a surface-based distance method. Med Phys. 2011;38(12):6730-6741.10.1118/1.3659707329856522149855
  18. [18] Molineu A, Followill DS, Balter PA, et al. Design and implementation of an anthropomorphic quality assurance phantom for intensity-modulated radiation therapy for the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2005;63(2):577-583.10.1016/j.ijrobp.2005.05.02116168849
  19. [19] Grégoire V, Mackie TR. State of the art on dose prescription, reporting and recording in Intensity-Modulated Radiation Therapy (ICRU report No. 83). Cancer Radiother. 2011;15(6-7):555-559.10.1016/j.canrad.2011.04.00321802333
  20. [20] Chaikh A, Desgranges C, Balosso J. Statistical methods to evaluate the correlation between measured and calculated dose using quality assurance method in IMRT. Int J Cancer Ther Oncol. 2015;3(4):10.14319/ijcto.34.11
  21. [21] Stock M, Kroupa B, Georg D. Interpretation and evaluation of the γ index and the γ index angle for the verification of IMRT hybrid plans. Phys Med Biol. 2005;50(3):399-411.10.1088/0031-9155/50/3/00115773719
  22. [22] Chung JB, Kim JS, Ha SW, Ye SJ. Statistical analysis of IMRT dosimetry quality assurance measurements for local delivery guideline. Radiat Oncol. 2011;6(1):27.10.1186/1748-717X-6-27307387521439096
  23. [23] Howell RM, Smith IP, Jarrio CS. Establishing action levels for EPID-based QA for IMRT. J Appl Clin Med Phys.2008;9(3):16-25.10.1120/jacmp.v9i3.2721572229418716584
  24. [24] van Zijtveld M, Dirkx ML, de Boer HC, Heijmen BJ. Dosimetric pre-treatment verification of IMRT using an EPID; clinical experience. Radiother Oncol. 2006;81(2):168-175.10.1016/j.radonc.2006.09.00817055604
  25. [25] Childress NL, White RA, Bloch C, et al. Retrospective analysis of 2D patient-specific IMRT verifications. Med Phys. 2005;32(4):838-850.10.1118/1.187927215895566
  26. [26] Fraass B, Doppke K, Hunt M, et al. American Association of Physicists in Medicine Radiation Therapy Committee Task Group 53: quality assurance for clinical radiotherapy treatment planning. Med Phys. 1998;25(10):1773-1829.10.1118/1.5983739800687
  27. [27] Jang SY, Liu HH, Mohan R. Underestimation of low-dose radiation in treatment planning of intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008;71(5):1537-1546.10.1016/j.ijrobp.2008.04.01418513883
  28. [28] Deng J, Pawlicki T, Chen Y, et al. The MLC tongue-and-groove effect on IMRT dose distributions. Phys Med Biol. 2001;46(4):1039-106010.1088/0031-9155/46/4/31011324950
  29. [29] Li JS, Lin T, Chen L, et al. Uncertainties in IMRT dosimetry. Med Phys. 2010;37(6):2491-2500.10.1118/1.341399720632560
  30. [30] Das IJ, Ding GX, Ahnesjö A. Small fields: nonequilibrium radiation dosimetry. Med Phys. 2008;35(1):206-215.10.1118/1.281535618293576
  31. [31] Ceberg C. A note on the interpretation of the gamma evaluation index. Journal of Physics: Conference Series. 2013;(444)1:012082.10.1088/1742-6596/444/1/012082
DOI: https://doi.org/10.1515/pjmpe-2017-0016 | Journal eISSN: 1898-0309 | Journal ISSN: 1425-4689
Language: English
Page range: 93 - 97
Submitted on: Jun 14, 2017
Accepted on: Oct 3, 2017
Published on: Dec 21, 2017
Published by: Polish Society of Medical Physics
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2017 Maria Atiq, Atia Atiq, Khalid Iqbal, Quratul ain Shamsi, Farah Andleeb, Saeed Ahmad Buzdar, published by Polish Society of Medical Physics
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.